Ramelteon: a novel treatment for the treatment of insomnia

Author: Wurtman, Richard

Source: Expert Review of Neurotherapeutics, Volume 6, Number 7, July 2006 , pp. 957-964(8)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Ramelteon, a potent agonist for the melatonin MT1 and MT2 brain receptors, has recently been granted approval by the US FDA for the treatment of insomnia associated with sleep onset. The drug has not exhibited potential for abuse or dependency in laboratory tests, nor does it interact with neurotransmitter receptors most associated with these phenomena, hence it has the great advantage of being a nonscheduled drug. Few data have been published in peer-reviewed journals describing its efficacy and side effects in patients with insomnia; however, side effects noted to date appear minor. No comparison study has been performed to determine whether the recommended dose of ramelteon 8 mg has any advantage over physiologic doses of melatonin (0.3 mg), particularly for long-term use.

Keywords: aging; downregulation; γ-aminobutyric acid receptors; melatonin; MT1 receptors; MT2 receptors; pineal; ramelteon; sleep

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14737175.6.7.957

Publication date: 2006-07-01

More about this publication?

Expert Review of Neurotherapeutics provides expert commentary on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer's and Parkinson's.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites